Moreover, a study showed that MPC2 predicted poor survival in patients with isocitrate dehydrogenase-mutant glioma [12], although the potential role of MPC2 in cancer, the clinical relevance, and molecular mechanism underlying its influence on CRC progression remain unknown. Here, MPC2 is linked to glioma.